Amy E. Herr Sells 1,860 Shares of Bio-Techne Co. (NASDAQ:TECH) Stock

Bio-Techne Co. (NASDAQ:TECH) Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares in the company, valued at $130,336.96. This represents a 48.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bio-Techne Price Performance

Shares of Bio-Techne stock traded down $0.65 during trading on Tuesday, hitting $65.29. 1,506,828 shares of the company were exchanged, compared to its average volume of 1,292,539. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a fifty-two week low of $61.16 and a fifty-two week high of $85.57. The stock has a market capitalization of $10.37 billion, a price-to-earnings ratio of 65.95, a P/E/G ratio of 5.54 and a beta of 1.27. The firm has a 50 day moving average price of $73.59 and a 200 day moving average price of $73.73.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. On average, equities analysts expect that Bio-Techne Co. will post 1.68 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Monday, February 17th will be issued a $0.08 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $0.32 annualized dividend and a yield of 0.49%. Bio-Techne’s dividend payout ratio (DPR) is presently 32.32%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. UMB Bank n.a. raised its holdings in Bio-Techne by 46.4% in the 4th quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Brooklyn Investment Group acquired a new position in Bio-Techne in the 3rd quarter valued at $39,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Bio-Techne during the 4th quarter valued at $41,000. Quest Partners LLC purchased a new stake in shares of Bio-Techne during the 3rd quarter valued at $43,000. Finally, GeoWealth Management LLC purchased a new stake in shares of Bio-Techne during the 4th quarter valued at $43,000. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TECH shares. Robert W. Baird lifted their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Royal Bank of Canada lifted their price target on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 6th. Scotiabank lifted their price target on shares of Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 6th. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, KeyCorp lifted their price target on shares of Bio-Techne from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.57.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.